

Prévention et dépistage

En pratique à Londres

Dr Gary Whitlock

Consultant in HIV & Sexual Health

56 Dean Street

Chelsea & Westminster Hospitals NHS Foundation Trust




Journées Thématiques Santé Sexuelle 2026



Declarations of interest


Gary Whitlock has received travel and research grants from & has been an advisor/speaker for ViiV, GSK & Gilead



Background

56 Dean Street (56DS)

- UK's busiest Sexual health & HIV clinic
 - London, England
 - National Health Service
 - Free-of-charge
-
- At 56DS
 - ~25,000 PrEP users
 - ~5300 individuals living with HIV



Services

- Walk-in
 - Emergency contraception
 - Acute symptoms/sexual assault
 - PEPSE
 - 28/7 Raltegravir 1.2g + Emtricitabine-tenofovir DF
 - PrEP initiation
 - Generic Emtricitabine-tenofovir DF
- Booked appointment
 - Non-acute symptoms/STI contact/treatment
 - Contraception
 - PrEP follow-up
 - HIV care

(Asymptomatic screening: e-Service “SHL”)




56DS Demographics




- 48,416 individuals attended in 2025
- Median age 34 (28-42)
- Under 25s = 5560/48416 = 11.5%
- Under 18 = 151/48416 = 0.3%

Attendances by age and gender between 02 Jan 2025 and 31 Dec 2025:




56DS Demographics

Attendances by ethnic category



Attendances by sexual orientation / gender



DoxyPEP

British Association for Sexual Health and HIV (BASHH) UK national guideline for the use of doxycycline post-exposure prophylaxis (DoxyPEP) for the prevention of syphilis, 2025

We recommend doxyPEP for cisgender GBMSM and TGW at elevated risk of acquiring syphilis (GRADE 1A). Individuals who may be at increased risk of acquiring syphilis include those with a recent (in the last year) bacterial STI diagnosis and those with a recent history (in the last 3 months) of multiple new, occasional, or one-off sexual partners, including reporting group-sex and chemsex.

Saunders J et al. BASHH UK national guideline for the use of doxycycline post-exposure prophylaxis (DoxyPEP) for the prevention of syphilis, 2025. Int J STD AIDS. 2025 36(10):756-764

Bexsero vaccine

| | |
|--|---|
| Clinical condition or situation to which this PGD applies | Indicated for GBMSM who are at higher risk of gonorrhoea in accordance with Gonorrhoea Chapter of Immunisation Against Infectious Disease: the Green Book and JCVI recommendations. |
| Criteria for inclusion | <p>GBMSM who are at higher risk of gonorrhoea include those:</p> <ul style="list-style-type: none">• who currently have or have had a bacterial sexually transmitted infection (STI) in the previous 12 months (see Special consideration and additional information) <p>OR</p> <ul style="list-style-type: none">• who are reporting at least 5 sexual partners in the previous 3 months <p>NOTE:</p> <p>Whilst gonorrhoea incidence remains the highest in the eligible GBMSM group (as defined above), sexual health clinical professionals may perform individual risk assessment and consider the offer of 4CMenB to the small numbers of individuals with an incidence of gonorrhoea approaching that in the eligible GBMSM group defined above. This may include sex workers</p> |

https://www.england.nhs.uk/south/wp-content/uploads/sites/6/2025/08/20250707UKHSA_Men_B__Gonorrhoea_v1.0a_GOV-19045-FINAL-1.pdf

Asymptomatic screening



Recommended testing frequencies for asymptomatic STI testing

| Risk group | Recommended testing frequency | Evidence |
|--|--|--------------------------------|
| Anyone with 1 long-term mutually exclusive partner | Test at start of relationship | (UKHSA, 2022) |
| Sexually active people | Annually and after partner change (maximum frequency 3 –monthly) | (UKHSA, 2022) |
| Sexually active people at high risk of STIs: <ul style="list-style-type: none">• PrEP users• >10 partners in last 12 months• Multiple or anonymous partners since last STI test• Sexualised drug use including chemsex• For 1 year after diagnosis of a bacterial STI | 3-monthly testing | (UKHSA, 2022) (Brady, 2018) |

BASHH summary guidance on testing for sexually transmitted infections, 2023




Services

- Walk-in
 - Emergency contraception
 - Acute symptoms/sexual assault
 - PEPSE
 - 28/7 Raltegravir 1.2g + Emtricitabine-tenofovir DF
 - PrEP initiation
 - Generic Emtricitabine-tenofovir DF
- Booked appointment
 - Chronic symptoms/STI contact/treatment
 - PrEP follow-up
 - HIV care

(Asymptomatic screening: e-Service “SHL”)





PrEP provision (91% nurse-led)



Whitlock et al. Nurse-led PrEP provision at 56 Dean Street. Lancet HIV. 2023 10(2):e81

HIV diagnoses, testing & PrEP



Whitlock et al. *HIV prevention in London, UK from 2017 to 2024: Outcomes, gaps and learnings*. HIV Medicine (2025)

STI testing in GBMSM, UK

Survey GBMSM, UK

- Nov-Dec 2024
- 2366 recommended 3-monthly testing
- 24.0% (562) tested ≥ 4 x yearly
- 28.7% (673) did not test in the past year

Findlater L et al. (2026) Characteristics associated with frequent sexually transmitted infection (STI) testing in a community-based sample of gay, bisexual, and other men who have sex with men (GBMSM), United Kingdom, 2024. PLOS Glob Public Health 6(3): e0005351



DoxyPEP

PrEP users, 56 Dean Street

- July 2018
- 8% (8/106) previously used antibiotics as prevention

August 2025

- Not available on NHS
- Info leaflet on website/in clinic
- Buy Doxycycline online



Carveth-Johnson T et al. Doxycycline use in MSM taking PrEP. Lancet HIV. 2018 5(9):e482

DoxyPEP & Bexsero: August 2025



GONORRHOEA VACCINE

DATE

1st

2nd



Find out more
www.dean.st




**BE PROTECTED WITH
DOXYPEP
& GONORRHOEA VAX**




Chelsea and Westminster Hospital **NHS**
NHS Foundation Trust

DoxyPEP uptake to Nov 25

- 17324 sexual health services attendees – 8914 (51%) were prescribed doxyPEP
- 8535/8914 (96%) identified as GBMSM and 148/8914 (2%) were transgender women



- 1911/8914 (21%) reported previous doxyPEP use, including 745/8914 (8%) in the previous month
- Of these 745, 3 doses is the median reported doxyPEP consumption in a month (IQR 2-4)



- 4CMenB was co-administered to 6649/8914 (75%) of doxyPEP starters
- Median of 2 STIs per person (IQR 1-2) in the 12 months preceding doxyPEP start


Girometti et al. Implementation of doxyPEP and 4x meningococcal B vaccination co-administration rates in a London sexual health service. BHIVA BASHH conference, Liverpool, UK (2026)

Bexsero vaccine

Bexsero vaccine

- 9717 individuals since introduction (1st +/- 2nd dose)
- Median age 38 y (32-46)

Attendances by age and gender between 04 Feb 2020 and 09 Mar 2026:



Bexsero vaccine

No UK response

- GoGoVax, CROI 2026
- Kent MenB outbreak, Mar 2026

Bexsero evaluation, UKHSA

- Real-life
- 6 English sexual health clinics
- >1100 vaccine recipients from 56DS

Kent meningitis outbreak prompts rush for routine vaccinations in England

Exclusive: Parental consents in Greater Manchester up 40% as demand surges in various parts of the country



CT, NG, syphilis diagnoses: Jul 25-Apr 26

Syphilis Testing and Diagnosis



Chlamydia Testing and Diagnosis



Gonorrhoea Testing and Diagnosis





Thank you

Email address: gwhitlock@nhs.net